Comment on: Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls: Reply

Ingrid Egeland Christensen¹, Siri Lillegraven¹, Till Uhlig^{1

2}, Sella Aarrestad Provan^{1

3}

Affiliations

¹ Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
³ Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway.

Ingrid Egeland Christensen et al. Rheumatol Adv Pract. 2025.

. 2025 Jun 5;9(3):rkaf069.

doi: 10.1093/rap/rkaf069. eCollection 2025.

Ingrid Egeland Christensen¹, Siri Lillegraven¹, Till Uhlig^{1

2}, Sella Aarrestad Provan^{1

3}

¹ Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
³ Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway.

No abstract available

References

1. Christensen IE, Lillegraven S, Sexton J. et al. Longitudinal risk of serious infections in patients with inflammatory arthritis on immunomodulating therapy compared to controls. Rheumatol Adv Pract 2025;9:rkaf017. - PMC - PubMed
1. Winthrop KL, Saag K, Cascino MD. et al. Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE Registry. Arthritis Care Res (Hoboken) 2018;71:993–1003. - PMC - PubMed
1. Grøn KL, Arkema EV, Glintborg B. et al. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis 2019;78:320–7. - PubMed
1. Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB.. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018;77:905–10. - PubMed